Recombinant Parainfluenza Virus 5 Vaccine Encoding the Influenza Virus Hemagglutinin Protects against H5N1 Highly Pathogenic Avian Influenza Virus Infection following Intranasal or Intramuscular Vaccination of BALB/c Mice
Authors:
Open Access
- 1 January 2013
- journal article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 87 (1) , 363-371
Abstract
New approaches for vaccination to prevent influenza virus infection are needed. Emerging viruses, such as the H5N1 highly pathogenic avian influenza (HPAI) virus, pose not only pandemic threats but also challenges in vaccine development and production. Parainfluenza virus 5 (PIV5) is an appealing vector for vaccine development, and we have previously shown that intranasal immunization with PIV5 expressing the hemagglutinin from influenza virus was protective against influenza virus challenge (S. M. Tompkins, Y. Lin, G. P. Leser, K. A. Kramer, D. L. Haas, E. W. Howerth, J. Xu, M. J. Kennett, J. E. Durbin, R. A. Tripp, R. A. Lamb, and B. He, Virology362:139–150, 2007). While intranasal immunization is an appealing approach, PIV5 may have the potential to be utilized in other formats, prompting us to test the efficacy of rPIV5-H5, which encodes the HA from H5N1 HPAI virus, in different vaccination schemes. In the BALB/c mouse model, a single intramuscular or intranasal immunization with a live rPIV5-H5 (ZL46) rapidly induced robust neutralizing serum antibody responses and protected against HPAI challenge, although mucosal IgA responses primed by intranasal immunization more effectively controlled virus replication in the lung. The rPIV5-H5 vaccine incorporated the H5 HA into the virion, so we tested the efficacy of an inactivated form of the vaccine. Inactivated rPIV5-H5 primed neutralizing serum antibody responses and controlled H5N1 virus replication; however, similar to other H5 antigen vaccines, it required a booster immunization to prime protective immune responses. Taken together, these results suggest that rPIV5-HA vaccines and H5-specific vaccines in particular can be utilized in multiple formats and by multiple routes of administration. This could avoid potential contraindications based on intranasal administration alone and provide opportunities for broader applications with the use of a single vaccine vector.Keywords
This publication has 51 references indexed in Scilit:
- A distinct lineage of influenza A virus from batsProceedings of the National Academy of Sciences of the United States of America, 2012
- Cold-Adapted Influenza and Recombinant Adenovirus Vaccines Induce Cross-Protective Immunity against pH1N1 Challenge in MicePLOS ONE, 2011
- Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccineProceedings of the National Academy of Sciences, 2009
- A Single Amino Acid Residue Change in the P Protein of Parainfluenza Virus 5 Elevates Viral Gene ExpressionJournal of Virology, 2008
- Inhibition of interleukin-6 expression by the V protein of parainfluenza virus 5Virology, 2007
- A dose–response evaluation of inactivated influenza vaccine given intranasally and intramuscularly to healthy young adultsVaccine, 2007
- Recombinant parainfluenza virus 5 (PIV5) expressing the influenza A virus hemagglutinin provides immunity in mice to influenza A virus challengeVirology, 2007
- Matrix Protein 2 Vaccination and Protection against Influenza Viruses, Including Subtype H5N1Emerging Infectious Diseases, 2007
- Cellular Immune Responses in Children and Adults Receiving Inactivated or Live Attenuated Influenza VaccinesJournal of Virology, 2006
- Immunity following intranasal administration of an inactivated, freeze-dried A/England/42/72 vaccineArchives of Virology, 1975